Subscribe: HSMN NewsFeed
http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
devices  feb healthcare  feb  healthcare sales  healthcare  marketing network  marketing  network  sales marketing  sales  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: HSMN NewsFeed

HSMN NewsFeed



Healthcare Sales & Marketing Network NewsFeed



Last Build Date: Tue, 20 Feb 2018 15:51:30 CST

 



Peritech Pharma's Novel Hemorrhoids Treatment Commercialized in 24 Countries

Tue, 20 Feb 2018 15:52:23 GMT

Deal includes local manufacturing and marketing in Central and South America, and the Caribbean HERZLIYA, Israel, Feb. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Peritech Pharma, a specialty anal-rectal pharmaceutical company, today announce...
Biopharmaceuticals, Licensing
Peritech Pharma, hemorrhoids



Johnson and Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics

Tue, 20 Feb 2018 14:08:42 GMT

PARIS, Feb. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced today the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery tech...
Devices, Mergers & Acquisitions
Johnson & Johnson, DePuy Synthes, Orthotaxy



Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology

Tue, 20 Feb 2018 13:45:42 GMT

Members include world-renowned experts in biomarker-defined cancers, bioengineering, drug discovery and clinical development CAMBRIDGE, Mass., Feb. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Merrimack Pharmaceuticals (Nasdaq: MACK), a clinic...
Biopharmaceuticals, Oncology, Personnel
Merrimack Pharmaceuticals



GenePOC Launches Its revogene(TM) Instrument and GBS LB Test in Canada

Mon, 19 Feb 2018 15:13:19 GMT

QUÉBEC CITY, February 19, 2018 -- (Healthcare Sales & Marketing Network) -- GenePOC Inc., member of the Debiopharm Group™, is proud to announce the launch in its home market for the revogene instrument and the GenePOC™ GBS LB assay. About Group ...
Diagnostics, Product Launch
GenePOC, Debiopharm, revogene, Group B Streptococcus



Blockchain Based Medical Device from NnBU Set to Raise €15million in ICO

Mon, 19 Feb 2018 14:02:49 GMT

New Neonatal Birth Unit is a World First to Improve Health Outcomes of Babies Born by C-Section NICOSIA, Cyprus, February 19, 2018 -- (Healthcare Sales & Marketing Network) --Today, Monday February 19 2018, NnBU Holdings Ltd (https://nnbu.io) announces...
Devices, Venture Capital
NnBU Holdings, blockchain, neonatal birth unit



AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity

Mon, 19 Feb 2018 13:35:48 GMT

Reductions in the impact of genital psoriasis on sexual activity seen as early as one week INDIANAPOLIS, Feb. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe ...
Biopharmaceuticals, Dermatology
Eli Lilly, Taltz, ixekizumab, genital psoriasis



Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors

Fri, 16 Feb 2018 15:43:33 GMT

CAMBRIDGE, Mass., Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately...
Biopharmaceuticals, Personnel
Editas Medicine, genomic medicine, CRISPR



Photocure Announces U.S. FDA Approval of New Indication for Blue Light Cystoscopy with Cysview(R)

Fri, 16 Feb 2018 15:36:38 GMT

OSLO, Norway, Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to extend the indication for Blue Lig...
Devices, Oncology, FDA
Photocure, KARL STORZ, Blue Light Cystoscopy, Cysview, bladder cancer



Arena Pharmaceuticals Announces Changes to Board of Directors

Fri, 16 Feb 2018 15:28:56 GMT

SAN DIEGO, Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H. Bice, Phillip M. Schneider, and Christine A. White, M.D. have indicated that they will be retiring from the Board of...
Biopharmaceuticals, Personnel
Arena Pharmaceuticals, pulmonary arterial hypertension, Crohn's disease



Perflow Medical Closes $12 Million in Financing to Treat Complex Neurovascular Disorders

Thu, 15 Feb 2018 15:15:03 GMT

Announces successful completion of over 50 commercial cases with the Stream™ Dynamic Neuro-Thrombectomy Net TEL AVIV, Israel, Feb. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Perflow Medical, an Israeli-based medical device company that devel...
Devices, Interventional, Neurology, Venture Capital
Perflow Medical, CEREBRAL NET, Thrombectomy



Viz.ai Granted De Novo FDA Clearance for First Artificial Intelligence Triage Software

Thu, 15 Feb 2018 15:10:56 GMT

A new era of intelligent stroke care begins as regulatory approval is granted for the Viz.ai LVO Stroke Platform The platform utilizes artificial intelligence to identify Large Vessel Occlusion (LVO) strokes and automatically notify specialists to speed...
Devices, Radiology, Neurology, FDA
Viz.ai, imaging, artificial intelligence, stroke



Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning

Thu, 15 Feb 2018 15:07:53 GMT

FDA clearance covers all solid tumors. Initial launch will include Liver AI and Lung AI oncology software to empower clinicians to quickly measure and track lesions and nodules in MRI and CT scans SAN FRANCISCO, Feb. 15, 2018 -- (Healthcare Sales & Mark...
Devices, Radiology, Oncology, FDA
Arterys, imaging, artificial intelligence



GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer

Thu, 15 Feb 2018 15:04:34 GMT

WASHINGTON, DC, February 15, 2018 -- (Healthcare Sales & Marketing Network) -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) ("GT" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercializat...
Biopharmaceuticals, Oncology, Personnel
GT Biopharma, lymphoma, leukemia



Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark

Thu, 15 Feb 2018 15:01:34 GMT

IRVINE, Calif., Feb. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has rece...
Devices, Cardiology, Regulatory
Edwards Lifesciences, CENTERA, self-expanding, TAVR, aortic valve



Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema

Wed, 14 Feb 2018 16:15:06 GMT

RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical out...
Biopharmaceuticals, Ophthalmology
Genentech, Roche Group, diabetic macular edema, Anti-VEGF, Anti-Angiopoietin-2



Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

Wed, 14 Feb 2018 16:07:09 GMT

BUENA, N.J., Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (A...
Biopharmaceuticals, Generics, FDA
Teligent, Betamethasone



Plastic And Reconstructive Surgery Journal Publishes Ten-Year Clinical Study Data Highlighting Safety Of MENTOR(R) MemoryShape(R) Gel Breast Implants

Wed, 14 Feb 2018 13:17:23 GMT

New publication adds to substantial clinical data demonstrating safety and effectiveness of MENTOR® Breast Implants in primary and revision augmentation and reconstruction patients IRVINE, Calif., Feb. 14, 2018 -- (Healthcare Sales & Marketing Netwo...
Devices, Surgery
Mentor Worldwide, Johnson & Johnson , MENTOR , MemoryShape, breast implant



Cantel Medical Promotes Lawrence Conway to Senior Vice President, Business Systems and Integration

Wed, 14 Feb 2018 13:08:36 GMT

LITTLE FALLS, N.J., Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- CANTEL MEDICAL CORP. (NYSE: CMD) announced today that Lawrence Conway has been recently appointed to Senior Vice President, Business Systems and Integration. In this role, Mr. ...
Devices, Personnel
Cantel Medical



Galmed Announces ARRIVE Study Data

Wed, 14 Feb 2018 13:03:15 GMT

TEL AVIV, Israel, Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver tar...
Biopharmaceuticals
Galmed Pharmaceuticals, Aramchol, nonalcoholic steatohepatitis



Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft(TM)C9T1 Skin Tissue

Wed, 14 Feb 2018 12:57:32 GMT

Study of Genetically Engineered Human Skin Substitute to Assess Safety and Tolerability in the Treatment of Diabetic Foot Ulcers STAINES-UPON-THAMES, United Kingdom, Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK...
Devices, Wound Care
Mallinckrodt, ExpressGraft-C9T1, diabetic foot ulcers



SanBio and Teijin to Terminate Licensing Agreement regarding SB623 for Stroke Treatment

Wed, 14 Feb 2018 12:48:12 GMT

Tokyo, Japan, February 14, 2018 --(Healthcare Sales & Marketing Network)-- SanBio, Inc. and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 f...
Biopharmaceuticals, Neurology, Licensing
Teijin, SanBio, stroke